Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial (Q46719660)

24 December 2017

http://europepmc.org/abstract/MED/16182896

title

Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial (English)

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

0 references

1 reference

Debasish Saha

1

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

Wasif A Khan

2

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

Mohammad M Karim

3

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

Hafizur R Chowdhury

4

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

Mohammed A Salam

5

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

Michael L Bennish

6

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

published in

The Lancet

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

volume

366

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

issue

9491

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

page(s)

1085-1093

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

cites work

TETRACYCLINE IN THE TREATMENT OF CHOLERA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Comparative trial of five antimicrobial compounds in the treatment of cholera in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Single-dose doxycycline for cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Single dose tetracycline in cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Randomised double blind trial of single dose doxycycline for treating cholera in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Efficacy of a single dose of furazolidone for treatment of cholera in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Emergence of multiply antibiotic-resistant Vibrio cholerae in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Safety profile of quinolone antibiotics in the pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Typhoid fever, ciprofloxacin and growth in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Treatment with ciprofloxacin in children with typhoid fever.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Serotype conversion in Vibrio cholerae O1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

PUBLIC HEALTH: Responding to Market Failures in Tuberculosis Control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

Expanding multiple antibiotic resistance among clinical strains of Vibrio cholerae isolated from 1992-7 in Calcutta, India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967290-X

7 January 2021

10.1016/S0140-6736(05)67290-X

Identifiers

DOI

1 reference

24 December 2017

http://europepmc.org/abstract/MED/16182896

1 reference

24 December 2017